BRPI1013901A2 - formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos - Google Patents
formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativosInfo
- Publication number
- BRPI1013901A2 BRPI1013901A2 BRPI1013901A BRPI1013901A BRPI1013901A2 BR PI1013901 A2 BRPI1013901 A2 BR PI1013901A2 BR PI1013901 A BRPI1013901 A BR PI1013901A BR PI1013901 A BRPI1013901 A BR PI1013901A BR PI1013901 A2 BRPI1013901 A2 BR PI1013901A2
- Authority
- BR
- Brazil
- Prior art keywords
- neuroprotection
- treatment
- neurodegenerative disorders
- clavulanate
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17384109P | 2009-04-29 | 2009-04-29 | |
| PCT/US2010/032983 WO2010127125A1 (en) | 2009-04-29 | 2010-04-29 | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013901A2 true BRPI1013901A2 (pt) | 2019-09-24 |
Family
ID=42261971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013901A BRPI1013901A2 (pt) | 2009-04-29 | 2010-04-29 | formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100255099A1 (pt) |
| EP (1) | EP2424498A1 (pt) |
| JP (1) | JP2012525427A (pt) |
| KR (1) | KR20120012823A (pt) |
| CN (1) | CN102413814A (pt) |
| AU (1) | AU2010242948A1 (pt) |
| BR (1) | BRPI1013901A2 (pt) |
| CA (1) | CA2758029A1 (pt) |
| IL (1) | IL215940A0 (pt) |
| MX (1) | MX2011011459A (pt) |
| WO (1) | WO2010127125A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
| US6610681B1 (en) * | 1999-08-16 | 2003-08-26 | Revaax Pharmaceuticals, Llc | Neurotherapeutic clavulanate composition and method |
| EP2214680A4 (en) * | 2007-10-26 | 2010-12-29 | Rexahn Pharmaceuticals Inc | PHARMACEUTICAL FORMULATION OF CLAVLANIC ACID |
| WO2013006808A2 (en) * | 2011-07-06 | 2013-01-10 | Rexahn Pharmaceuticals, Inc. | Clavulanic acid for treatment of restless legs syndrome |
| US8978166B2 (en) * | 2012-08-27 | 2015-03-17 | Well & David Corp. | Multi-function garment |
| CN106535931A (zh) * | 2014-08-25 | 2017-03-22 | 艾慕恩治疗公司 | 卵蛋白制剂及其制备方法 |
| CA2988918A1 (en) | 2015-06-19 | 2016-12-22 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN113454456B (zh) * | 2019-04-15 | 2024-08-20 | 纳诺洛吉卡股份公司 | 用于治疗、预防和/或延缓神经退行性疾病以及神经元和神经胶质退化的空多孔颗粒 |
| CN112843034B (zh) * | 2019-11-26 | 2022-08-23 | 亚瑟瑞智科技管理顾问股份有限公司 | 包含克拉维酸与丙戊酸的组合物及其用途 |
| TWI739220B (zh) * | 2019-11-26 | 2021-09-11 | 亞瑟瑞智科技管理顧問股份有限公司 | 包含克拉維酸與丙戊酸之組合物及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110165A (en) * | 1974-04-20 | 1978-08-29 | Beecham Group Limited | Process for the production of clavulanic acid |
| CA1085392A (en) * | 1976-03-25 | 1980-09-09 | Masayuki Narisada | Arylmalonamido-1-oxadethiacephalosporins |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4234579A (en) * | 1977-06-07 | 1980-11-18 | Pfizer Inc. | Penicillanic acid 1,1-dioxides as β-lactamase inhibitors |
| JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
| NZ189022A (en) * | 1977-12-08 | 1981-11-19 | Beecham Group Ltd | Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder |
| US4273763A (en) * | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
| US4268503A (en) * | 1978-09-14 | 1981-05-19 | Fujisawa Pharmaceutical Co., Ltd. | Antibacterial composition |
| DE3001961C2 (de) * | 1980-01-21 | 1984-08-16 | Didier Engineering Gmbh, 4300 Essen | Anströmboden für einen Wirbelschichtreaktor |
| NZ198241A (en) * | 1980-09-27 | 1983-12-16 | Beecham Group Ltd | Tablet containing amoxycillin and potassium clavulanate |
| US4594247A (en) * | 1981-12-21 | 1986-06-10 | Eli Lilly And Company | Synergistic antibacterial compositions and method of treatment of infections caused by multiple antibiotic-resistant organisms |
| JPS59104389A (ja) * | 1982-12-06 | 1984-06-16 | Shionogi & Co Ltd | オキサセファム誘導体 |
| JPS62106015A (ja) * | 1985-10-31 | 1987-05-16 | Sumitomo Pharmaceut Co Ltd | 抗痴呆薬 |
| US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| GB9201639D0 (en) * | 1992-01-25 | 1992-03-11 | Smithkline Beecham Plc | Pharmaceutical formulations |
| GB9215908D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Water dispersible tablets |
| US5643909A (en) * | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| EP0678095A1 (en) * | 1993-11-06 | 1995-10-25 | Taiho Pharmaceutical Co., Ltd. | Crystalline penicillin derivative, and its production and use |
| US5827537A (en) * | 1995-05-04 | 1998-10-27 | Smithkline Beecham Corporation | Pharmaceutical thermal infusion process |
| GB9515411D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| GB9525697D0 (en) * | 1995-12-15 | 1996-02-14 | Pharmacia Spa | Cephem derivatives |
| DE69734321T2 (de) * | 1996-02-23 | 2006-08-10 | Eli Lilly And Co., Indianapolis | Non-peptidische vasopressin via antagonisten |
| US5905076A (en) * | 1996-04-10 | 1999-05-18 | National Research Council Of Canada | 6-substituted amino-4-oxa-1-azabicyclo 3,2,0! heptan-7-one derivatives as cysteine protease inhibitors |
| US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US6017903A (en) * | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5977090A (en) * | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US6075014A (en) * | 1997-06-13 | 2000-06-13 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
| US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| US6177421B1 (en) * | 1999-05-04 | 2001-01-23 | Fuisz International Ltd. | Amoxicillin and clavulanate composition |
| ATE424191T1 (de) * | 1999-02-04 | 2009-03-15 | Abbott Lab | Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung |
| IE990159A1 (en) * | 1999-02-26 | 2000-09-20 | Fuisz Internat Ltd | Storage Stable Amoxycillin and Clavulanate Suspension Composition. |
| AU770599B2 (en) * | 1999-07-06 | 2004-02-26 | Methylgene Inc. | Sulfonamidomethyl phosphonate inhibitors of beta-lactamase |
| US6610681B1 (en) * | 1999-08-16 | 2003-08-26 | Revaax Pharmaceuticals, Llc | Neurotherapeutic clavulanate composition and method |
| US6489319B2 (en) * | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
| US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
| ES2258988T3 (es) * | 1999-12-22 | 2006-09-16 | Pharmacia Corporation | Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2. |
| US20020013270A1 (en) * | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| ATE286057T1 (de) * | 2000-10-20 | 2005-01-15 | Sandoz Ag | Pharmazeutische zubereitungen enthaltend clavulansäure |
| WO2002102378A1 (en) * | 2001-06-18 | 2002-12-27 | Revaax Pharmaceuticals, Llc | Therapeutic treatment for sexual dysfunction |
| DE60319802T2 (de) * | 2002-01-10 | 2008-07-10 | Biovail Laboratories International S.R.L. | Sedierende nicht-benzodiazepin-formulierungen |
| IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| MXPA06002125A (es) * | 2003-08-25 | 2006-05-31 | Revaax Pharmaceuticals Llc | Composiciones orales de cefazolin neuroterapeutico. |
| PL1776109T3 (pl) * | 2004-08-13 | 2009-06-30 | Schering Plough Ltd | Farmaceutyczna formulacja zawierająca antybiotyk, triazol i kortykosteroid |
| US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
| SI21912A (sl) * | 2004-12-24 | 2006-06-30 | Lek Farmacevtska Druzba D.D. | Stabilne farmacevtske oblike, ki vsebujejo amoksicilin in klavulansko kislino |
| DE102006007830A1 (de) * | 2006-02-17 | 2007-08-30 | Grünenthal GmbH | Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure |
| MX2008012260A (es) * | 2006-03-24 | 2008-10-07 | Panacea Biotec Ltd | Composiciones antibioticas de liberacion modificada y procedimiento para su produccion. |
| US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
| EP2214680A4 (en) * | 2007-10-26 | 2010-12-29 | Rexahn Pharmaceuticals Inc | PHARMACEUTICAL FORMULATION OF CLAVLANIC ACID |
-
2010
- 2010-04-29 MX MX2011011459A patent/MX2011011459A/es unknown
- 2010-04-29 CN CN2010800184471A patent/CN102413814A/zh active Pending
- 2010-04-29 JP JP2012508734A patent/JP2012525427A/ja active Pending
- 2010-04-29 KR KR1020117028280A patent/KR20120012823A/ko not_active Withdrawn
- 2010-04-29 US US12/770,304 patent/US20100255099A1/en not_active Abandoned
- 2010-04-29 EP EP10717387A patent/EP2424498A1/en not_active Withdrawn
- 2010-04-29 CA CA2758029A patent/CA2758029A1/en not_active Abandoned
- 2010-04-29 BR BRPI1013901A patent/BRPI1013901A2/pt not_active IP Right Cessation
- 2010-04-29 WO PCT/US2010/032983 patent/WO2010127125A1/en not_active Ceased
- 2010-04-29 AU AU2010242948A patent/AU2010242948A1/en not_active Abandoned
-
2011
- 2011-10-26 IL IL215940A patent/IL215940A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2424498A1 (en) | 2012-03-07 |
| CA2758029A1 (en) | 2011-11-04 |
| IL215940A0 (en) | 2012-01-31 |
| WO2010127125A1 (en) | 2010-11-04 |
| KR20120012823A (ko) | 2012-02-10 |
| AU2010242948A1 (en) | 2011-11-24 |
| US20100255099A1 (en) | 2010-10-07 |
| MX2011011459A (es) | 2011-11-18 |
| JP2012525427A (ja) | 2012-10-22 |
| CN102413814A (zh) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257581A (en) | New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| PL2512470T3 (pl) | Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych | |
| BRPI0810082A2 (pt) | 3-imidazolil-indóis para o tratamento de doenças proliferativas | |
| BRPI1015569A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias. | |
| EP2552433A4 (en) | COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES | |
| IL215940A0 (en) | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders | |
| BR112013014943A2 (pt) | compostos úteis para o tratamento de aids | |
| WO2011049960A9 (en) | Compositions and methods for the treatment of sinonasal disorders | |
| BRPI1014759A2 (pt) | composto útil para o tratamento de doenças degenerativas e inflamatórias | |
| IL217901A0 (en) | Treatment of bdnf-related disorders using laquninimod | |
| BRPI0813516A2 (pt) | Tratamento de distúrbios proliferativos de células b | |
| ZA201202596B (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| PL2437742T3 (pl) | Nowe kompozycje do leczenia cmt i pokrewnych zaburzeń | |
| BR112012004836A2 (pt) | pirazinilpiridinas úteis para o tratamento de doenças proliferativas | |
| BR112014013843A2 (pt) | uso de dispositivos para o tratamento de doenças neurológicas | |
| CO6801724A2 (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
| PT2632300T (pt) | Almofada cervical para o tratamento de doenças da coluna cervical | |
| HUE040085T2 (hu) | PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére | |
| BR112014004416A2 (pt) | composições e métodos para o tratamento de doenças neurodegenerativas | |
| PL2582366T3 (pl) | Kombinacja farmaceutyczna do leczenia bólu | |
| IL223725B (en) | Formulations of rifaximin and uses thereof | |
| CO6801718A2 (es) | Composición terapéutica para el tratamiento de glioblastoma | |
| BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia | |
| PT2632475T (pt) | Composições para o tratamento de úlceras periféricas de várias origens | |
| BRPI0812034A2 (pt) | Combinações de neramexano para o tratamento de distúrbios neurodegenerativos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |